跳到正文
原文
Medical Xpress·· 28 天前精选AI 评分76

肺癌肿瘤中的“关闭开关”或解释免疫治疗对部分患者无效的原因

Overlooked 'off switch' in lung tumors may explain why immunotherapy doesn't work for everyone

AI 导读

Jackson实验室团队在《科学》杂志发表研究,发现肺癌通过RNA替代剪接产生不同版本的STAT2基因,而非基因突变来削弱其功能。基于两项大型临床数据分析,带有内含子保留的STAT2 RNA剪接特征与阿替利珠单抗免疫治疗后患者生存期延长相关。

推荐理由

研究通过RNA剪接机制识别免疫治疗应答标志,为肺癌精准用药提供新思路。

正文 · 原文
Overlooked 'off switch' in lung tumors may explain why immunotherapy doesn't work for everyone
New research shows that human lung cancers use a process called alternative RNA splicing to produce different versions (isoforms) of the immune-alarm gene STAT2, shown here as ribbons. Isoforms of STAT2 are associated with how well lung cancer patients respond to immunotherapy: an isoform that retains an extra segment called an intron (top ribbon) is found in patients who respond to anti-PD-L1, while an isoform without it (bottom ribbon) is found in nonresponders. These splicing signatures could one day help doctors predict, before treatment begins, which patients are most likely to benefit from immunotherapy. Credit: The Jackson Laboratory

An overlooked mechanism in lung cancer tumors may help explain why most patients don't respond to immunotherapy, according to new research led by Olga Anczuków, professor at The Jackson Laboratory for Genomic Medicine in Farmington, Connecticut, and deputy director of the NCI-designated Jackson Laboratory Cancer Center.

The JAX team includes co-senior author Karolina Palucka, professor and director of the NCI-designated Jackson Laboratory Cancer Center, and Ryan P. Englander, the study's first author and a graduate student at The Jackson Laboratory enrolled in the UConn Health MD-Ph.D. graduate program.

Published in Science, the study shows that lung tumors can disable a key gene called STAT2, not through mutations, but instead by altering how its RNA instructions are processed through a mechanism known as RNA splicing. Using long-read RNA sequencing, the team discovered thousands of previously unrecognized RNA variants in lung tumors.

Based on an analysis of two large clinical trials of the immunotherapy drug atezolizumab, specific STAT2 RNA splicing patterns were associated with longer survival after immunotherapy. Most reference databases used in cancer research and testing do not include these newly discovered splicing patterns.

The researchers have filed a provisional patent application for correcting this splicing mistake with RNA-based drugs, as well as for predicting immunotherapy response.

Publication details

Ryan P. Englander et al., Intron retention regulates STAT2 function and associates with immunotherapy response in lung cancer, Science (2026). DOI: 10.1126/science.aea7156

Journal information: Science

Clinical categories

Oncology

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Overlooked 'off switch' in lung tumors may explain why immunotherapy doesn't work for everyone (2026, October 23) retrieved 23 October 2026 from https://medicalxpress.com/news/2026-10-overlooked-lung-tumors-immunotherapy-doesnt.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com